|
1
|
Chen YP, Chan ATC, Le QT, Blanchard P, Sun
Y and Ma J: Nasopharyngeal carcinoma. Lancet. 394:64–80. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee AW, Ng WT, Chan LL, Hung WM, Chan CC,
Sze HC, Chan OS, Chang AT and Yeung RM: Evolution of treatment for
nasopharyngeal cancer - success and setback in the
intensity-modulated radiotherapy era. Radiother Oncol. 110:377–384.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Colevas AD, Yom SS, Pfister DG, Spencer S,
Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ,
et al: NCCN Guidelines Insights: Head and Neck Cancers, Version
1.2018. J Natl Compr Canc Netw. 16:479–490. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD,
Yang KY, Jin F, Shi M, Chen YP, Hu WH, et al: Gemcitabine and
Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N
Engl J Med. 381:1124–1135. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang YM, Qiao SQ, Lu L, Chen WP, Li SL
and Qi CH: Gemcitabine combined with cisplatin vs. taxane,
cisplatin, and fluorouracil in the treatment of locally advanced
nasopharyngeal carcinoma: A retrospective case-control study. Eur
Rev Med Pharmacol Sci. 24:7655–7663. 2020.PubMed/NCBI
|
|
7
|
Lu Y, Chen D, Liang J, Gao J, Luo Z, Wang
R, Liu W, Huang C, Ning X, Liu M, et al: Administration of
nimotuzumab combined with cisplatin plus 5-fluorouracil as
induction therapy improves treatment response and tolerance in
patients with locally advanced nasopharyngeal carcinoma receiving
concurrent radiochemotherapy: A multicenter randomized controlled
study. BMC Cancer. 19:12622019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jin T, Qin WF, Jiang F, Jin QF, Wei QC,
Jia YS, Sun XN, Li WF and Chen XZ: Cisplatin and Fluorouracil
Induction Chemotherapy With or Without Docetaxel in Locoregionally
Advanced Nasopharyngeal Carcinoma. Transl Oncol. 12:633–639. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Y, Li S, Meng X, Gan RY, Zhang JJ and
Li HB: Dietary Natural Products for Prevention and Treatment of
Breast Cancer. Nutrients. 9:E7282017. View Article : Google Scholar
|
|
10
|
Luo H, Vong CT, Chen H, Gao Y, Lyu P, Qiu
L, Zhao M, Liu Q, Cheng Z, Zou J, et al: Naturally occurring
anti-cancer compounds: Shining from Chinese herbal medicine. Chin
Med. 14:482019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tuli HS, Sharma AK, Sandhu SS and Kashyap
D: Cordycepin: A bioactive metabolite with therapeutic potential.
Life Sci. 93:863–869. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu X, Shen H, Yin X, Long L, Xie C, Liu
Y, Hui L, Lin X, Fang Y, Cao Y, et al: miR-186 regulation of Twist1
and ovarian cancer sensitivity to cisplatin. Oncogene. 35:323–332.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo Z, Chen W, Dai G and Huang Y:
Cordycepin suppresses the migration and invasion of human liver
cancer cells by downregulating the expression of CXCR4. Int J Mol
Med. 45:141–150. 2020.PubMed/NCBI
|
|
14
|
Ho SY, Wu WS, Lin LC, Wu YH, Chiu HW, Yeh
YL, Huang BM and Wang YJ: Cordycepin Enhances Radiosensitivity in
Oral Squamous Carcinoma Cells by Inducing Autophagy and Apoptosis
Through Cell Cycle Arrest. Int J Mol Sci. 20:E53662019. View Article : Google Scholar
|
|
15
|
Wei C, Yao X, Jiang Z, Wang Y, Zhang D,
Chen X, Fan X, Xie C, Cheng J, Fu J, et al: Cordycepin Inhibits
Drug-resistance Non-small Cell Lung Cancer Progression by
Activating AMPK Signaling Pathway. Pharmacol Res. 144:79–89. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Khan MA and Tania M: Cordycepin in
Anticancer Research: Molecular Mechanism of Therapeutic Effects.
Curr Med Chem. 27:983–996. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoon SY, Park SJ and Park YJ: The
Anticancer Properties of Cordycepin and Their Underlying
Mechanisms. Int J Mol Sci. 19:E30272018. View Article : Google Scholar
|
|
18
|
Knapek KJ, Georges HM, Van Campen H,
Bishop JV, Bielefeldt-Ohmann H, Smirnova NP and Hansen TR: Fetal
Lymphoid Organ Immune Responses to Transient and Persistent
Infection with Bovine Viral Diarrhea Virus. Viruses. 12:E8162020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW,
Tsang YS, Wong N, Whitney BM and Lee JC: Nasopharyngeal carcinoma
cell line (C666-1) consistently harbouring Epstein-Barr virus. Int
J Cancer. 83:121–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chang MM, Hong SY, Yang SH, Wu CC, Wang CY
and Huang BM: Anti-Cancer Effect of Cordycepin on FGF9-Induced
Testicular Tumorigenesis. Int J Mol Sci. 21:E83362020. View Article : Google Scholar
|
|
21
|
Wang Z, Wu X, Liang YN, Wang L, Song ZX,
Liu JL and Tang ZS: Cordycepin Induces Apoptosis and Inhibits
Proliferation of Human Lung Cancer Cell Line H1975 via Inhibiting
the Phosphorylation of EGFR. Molecules. 21:E12672016. View Article : Google Scholar
|
|
22
|
Chen Y, Yang SH, Hueng DY, Syu JP, Liao CC
and Wu YC: Cordycepin induces apoptosis of C6 glioma cells through
the adenosine 2A receptor-p53-caspase-7-PARP pathway. Chem Biol
Interact. 216:17–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee SY, Debnath T, Kim SK and Lim BO:
Anti-cancer effect and apoptosis induction of cordycepin through
DR3 pathway in the human colonic cancer cell HT-29. Food Chemical
Toxicol. 60:439–447. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tao X, Ning Y, Zhao X and Pan T: The
effects of cordycepin on the cell proliferation, migration and
apoptosis in human lung cancer cell lines A549 and NCI-H460. J
Pharm Pharmacol. 68:901–911. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li XY, Tao H, Jin C, Du ZY, Liao WF, Tang
QJ and Ding K: Cordycepin inhibits pancreatic cancer cell growth in
vitro and in vivo via targeting FGFR2 and blocking ERK signaling.
Chin J Nat Med. 18:345–355. 2020.PubMed/NCBI
|
|
26
|
Chen YH, Wang JY, Pan BS, Mu YF, Lai MS,
So EC, Wong TS and Huang BM: Cordycepin enhances cisplatin
apoptotic effect through caspase/MAPK pathways in human head and
neck tumor cells. OncoTargets Ther. 6:983–998. 2013.PubMed/NCBI
|
|
27
|
Gao Y, Chen DL, Zhou M, Zheng ZS, He MF,
Huang S, Liao XZ and Zhang JX: Cordycepin enhances the
chemosensitivity of esophageal cancer cells to cisplatin by
inducing the activation of AMPK and suppressing the AKT signaling
pathway. Cell Death Dis. 11:8662020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Krishnamurthy N and Kurzrock R: Targeting
the Wnt/beta-catenin pathway in cancer: Update on effectors and
inhibitors. Cancer Treat Rev. 62:50–60. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Su NW, Wu SH, Chi CW, Liu CJ, Tsai TH and
Chen YJ: Metronomic Cordycepin Therapy Prolongs Survival of Oral
Cancer-Bearing Mice and Inhibits Epithelial-Mesenchymal Transition.
Molecules. 22:E6292017. View Article : Google Scholar
|
|
31
|
Liu T, Zhu G, Yan W, Lv Y, Wang X, Jin G,
Cui M, Lin Z and Ren X: Cordycepin Inhibits Cancer Cell
Proliferation and Angiogenesis through a DEK Interaction via ERK
Signaling in Cholangiocarcinoma. J Pharmacol Exp Ther. 373:279–289.
2020. View Article : Google Scholar : PubMed/NCBI
|
